Literature DB >> 10068211

Detailed in vivo analysis of interferon-gamma induced major histocompatibility complex expression in the the central nervous system: astrocytes fail to express major histocompatibility complex class I and II molecules.

M S Horwitz1, C F Evans, F G Klier, M B Oldstone.   

Abstract

To recognize and respond immunologically to foreign antigens, T lymphocytes require the presentation of foreign peptides by MHC molecules. To determine which cells of the central nervous system (CNS) are capable of expressing MHC molecules, we used confocal microscopy and dual immunofluorescence with cell-specific and MHC-specific antibodies to study brain sections of adult mice. We took advantage of transgenic mice that initiate CNS-specific expression of IFN-gamma at 8 weeks of age. This inflammatory cytokine is a strong inducer of MHC expression both in culture and in vivo. From this analysis, we clearly found MHC class I and II expression on endothelial, microglial, and oligodendrocyte cell types, but did not find astrocytes or neurons capable of expressing either MHC class I or II molecules under these conditions. This finding suggests that, although microglia and oligodendrocytes may participate in the antigen presentation process in the organism, we found no in vivo evidence to support the concept that astrocytes act as antigen-presenting cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10068211

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  29 in total

1.  Role of viral persistence in retaining CD8(+) T cells within the central nervous system.

Authors:  N W Marten; S A Stohlman; C C Bergmann
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Cerebral endothelial activation and signal transduction mechanisms during inflammation and infectious disease.

Authors:  R N Kalaria
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

Review 3.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 4.  Future trends in neurovirology: neuronal survival during virus infection and analysis of virus-specific T cells in central nervous system tissues.

Authors:  Michael B A Oldstone
Journal:  J Neurovirol       Date:  2004-08       Impact factor: 2.643

5.  An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme.

Authors:  Abdeljabar El Andaloussi; Maciej S Lesniak
Journal:  Neuro Oncol       Date:  2006-05-24       Impact factor: 12.300

6.  What Kaplan-Meier survival curves don't tell us about CNS disease.

Authors:  Katelyn D Miller; Glenn F Rall
Journal:  J Neuroimmunol       Date:  2017-02-03       Impact factor: 3.478

7.  Rapid formation of extended processes and engagement of Theiler's virus-infected neurons by CNS-infiltrating CD8 T cells.

Authors:  Jeremiah R McDole; Steve C Danzer; Raymund Y K Pun; Yi Chen; Holly L Johnson; Istvan Pirko; Aaron J Johnson
Journal:  Am J Pathol       Date:  2010-09-02       Impact factor: 4.307

8.  Persistent viral infection elevates central nervous system MHC class I through chronic production of interferons.

Authors:  Phi Truong; Sara Heydari; Lucile Garidou; Dorian B McGavern
Journal:  J Immunol       Date:  2009-08-28       Impact factor: 5.422

9.  Type I interferons are essential in controlling neurotropic coronavirus infection irrespective of functional CD8 T cells.

Authors:  Derek D C Ireland; Stephen A Stohlman; David R Hinton; Roscoe Atkinson; Cornelia C Bergmann
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

10.  Transgenic mice expressing the nucleoprotein of Borna disease virus in either neurons or astrocytes: decreased susceptibility to homotypic infection and disease.

Authors:  Mathias Rauer; Jürgen Götz; Daniel Schuppli; Peter Staeheli; Jürgen Hausmann
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.